Clinical Trial Update: TACE Combined With Immune Checkpoint Inhibitors for Liver Malignant Tumors [NA]

View source ↗

Summary

This clinical trial assesses the combination of transarterial chemoembolization (TACE) with immune checkpoint inhibitors for non-resectable liver cancers and is…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cholangiocarcinoma
• Hepatocellular Carcinoma
• Liver Metastases

Snippet

Sponsor: Tianjin Medical University Cancer Institute and Hospital | Conditions: Hepatocellular Carcinoma Non-resectable, Cholangiocarcinoma Non-resectable | NA | Status: RECRUITING